You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Tapeworm drug, masks are part of Reliance's plan to tackle coronavirus

Reliance Industries is exploring use of a tapeworm drug, Niclosamide, as a cure for Covid-19, according to its annual report.

Topics
Coronavirus | Reliance Industries | Coronavirus Tests

Debjit Chakraborty | Bloomberg 

Photo: Bloomberg
Photo: Bloomberg

Ltd. is working on a new Covid-19 drug and cheaper testing kits as the conglomerate owned by Asia’s richest man Mukesh Ambani looks to curb the pathogen which has ravaged India in the past year.

India’s most-valuable company is exploring use of a tapeworm drug, Niclosamide, as a cure for Covid-19, according to its annual report. Its diagnostic kits -- R-Green and R-Green Pro -- have been approved by India’s apex medical research body and it has designed a process to make sanitizers at one-fifth the market cost, Reliance said in the report.

ALSO READ: India Covid update: 134,000 coronavirus cases, 2,887 deaths in 24 hrs

The refining-to-retail group’s efforts come as India emerges the pandemic’s epicenter with the world’s fastest-surging outbreak that has sickened 28.44 million so far and killed more than 337,900 people in the Asian nation. Even though the deadly second wave is ebbing, experts have warned against a possible third wave of infections.


Tapeworm drug, masks are part of Reliance's plan to tackle coronavirus

Reliance is also trying to address ventilator shortages across Indian hospitals seen earlier this year by using 3D technology and a “special snorkeling mask.” It is designing medical-grade oxygen generators with five to seven liter capacity per minute, the report said.

When India faced a huge oxygen shortage during the second wave in April, Reliance repurposed its plants in Jamnagar, world’s biggest oil refinery site, to produce medical-grade oxygen. Last year, it set up a unit to make personal protective equipment kits for the front-line health care workers.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, June 03 2021. 15:08 IST
RECOMMENDED FOR YOU